SNW(SH:600628) Sou Hu Cai Jing·2025-11-21 23:27Core Viewpoint - The company has approved the continued use of raised funds to purchase financial products or structured deposits, aiming to enhance fund utilization efficiency while ensuring that it does not affect the construction of investment projects or the use of raised funds [2][14]. Summary by Sections Fundraising Overview - The company raised a total of 1,315,319,983.02 RMB through a non-public offering of 115,076,114 shares at a price of 11.43 RMB per share, with a net amount of 1,303,670,100.75 RMB after deducting various fees [2][4]. Fund Management - The company has established a special account for the management and storage of raised funds, ensuring that all funds are deposited in a board-approved special account and are subject to regulatory agreements with the sponsoring institution and the commercial bank [3]. Investment Projects - The company has adjusted its investment projects, reallocating funds from the "Health Industry Expansion Project" to invest 45,800.58 million RMB in the "Traditional Chinese Medicine Production Base Construction Project" [5]. Cash Management - The company plans to use up to 850 million RMB of idle raised funds for purchasing safe, liquid financial products or structured deposits with a capital preservation commitment, with the authority to make investment decisions granted to the chairman or CFO [10][14]. Risk Control Measures - The company will select financial products from issuers that can provide capital preservation guarantees, ensuring high safety and liquidity, and will not affect the normal operation of the investment projects [15][17]. Approval Process - The decision to continue using idle raised funds for financial products was approved by the board's audit committee and the board of directors, confirming compliance with relevant regulations and ensuring that it aligns with the interests of the company and its shareholders [13][18].